Emergence of new classes of recreational drugs - Synthetic cannabinoids and cathinones

Journal of General Internal Medicine

Volumn 29, Issue 8, 2014, Pages 1200-1204

  Khullar, Vikas ^a   Jain, Ankur ^a   Sattari, Maryam ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

bath salts; designer drugs; synthetic cannabinoids; synthetic cathinones

Indexed keywords

AMPHETAMINE; CANNABINOID; CANNABIS; CATHINONE; COCAINE; CREATINE KINASE; DESIGNER DRUG; HALOPERIDOL; INFUSION FLUID; INORGANIC SALT; LORAZEPAM; RECREATIONAL DRUG; ALKALOID; STREET DRUG;

ACUTE PSYCHOSIS; ADULT; AGITATION; ARTICLE; AWARENESS; BLOOD PRESSURE; CASE REPORT; CLINICAL FEATURE; COLLEGE STUDENT; CREATINE KINASE BLOOD LEVEL; DRUG INTOXICATION; DRUG SCREENING; HALLUCINATION; HEART RATE; HISPANIC; HUMAN; MALE; MENTAL HEALTH; ORAL REHYDRATION THERAPY; POLICE; SHIVERING; SUBSTANCE ABUSE; URINALYSIS; YOUNG ADULT; SUBSTANCE-RELATED DISORDERS; SYNTHESIS;

ALKALOIDS; CANNABINOIDS; HUMANS; MALE; STREET DRUGS; SUBSTANCE-RELATED DISORDERS; YOUNG ADULT;

EID: 84904412824     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1007/s11606-014-2802-4     Document Type: Article

References (41)

1. Monitoring the Future - National Results on AdolescentDrug Use:Overview of Key Findings, 2011. 2013; http://www.monitoringthefuture.org/pubs/monographs/ mtf-overview2011.pdf. Accessed October 18, 2013.
2. Kalant H. Adverse effects of cannabis on health: an update of the literature since 1996. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28(5):849-63. (Pubitemid 39195275)
3. Bronstein AC, Spyker DA, Cantilena LR Jr, Green JL, Rumack BH, Dart RC. 2010 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 28th Annual Report. Clin Toxicol (Phila). 2011;49(10):910-41.
4. News from DEA, Domestic Field Divisions, Washington DC News Releases, 11/24/10. DEA Moves to Emergency Control Synthetic Marijuana 2013; http://www.justice.gov/dea/pubs/pressrel/pr112410.html. Accessed October 18, 2013.
5. News from DEA, News Releases, 09/07/11. DEA Moves to Emergency Control Synthetic Stimulants 2013; http://www.justice.gov/dea/pubs/pressrel/pr090711p. html. Accessed October 18, 2013.
6. Emergency Department Visits After Use of a Drug Sold as "Bath Salts" - Michigan, November 13, 2010 - March 31, 2011. 2013; http://www.cdc.gov/mmwr/pdf/wk/mm6019.pdf. Accessed October 18, 2013.
7. Gershman JA, Fass AD. Synthetic cathinones ('bath salts'): legal and health care challenges. P T. 2012;37(10):571-95.
8. "Bath Salts" - Emerging and Dangerous Products | National Institute on Drug Abuse. 2013; http://www.drugabuse.gov/about-nida/directors- page/messages-director/2011/02/bath-salts-emerging-dangerous-products. Accessed October 18, 2013.
9. U.S. Department of Justice. Drug Enforcement Administration Background, Data, and Analysis of Synthetic Cathinones: Mephedrone (4-MMC), Methylone (MDMC), and 3,4-methylene dioxypyrovalerone (MDPV) Aug, 2011. 2013; http://www.deadiversion.usdoj.gov/fed-regs/rules/2011/HHS%20PDF/background.pdf. Accessed October 18, 2013.
10. Ross EA, Watson M, Goldberger B. "Bath salts" intoxication. N Engl J Med. 2011;365(10):967-8.
11. El Paso IntelligenceCenter.El Paso Intelligence Center, Synthetic stimulants marketed as bath salts. 2011. 2013; http://info.publicintelligence. net/EPIC-BathSalts.pdf. Accessed October 18, 2013.
12. Fass JA, Fass AD, Garcia AS. Synthetic cathinones (bath salts): legal status and patterns of abuse. Ann Pharmacother. 2012;46(3):436-41.
13. Smith C, Cardile AP, Miller M. Bath salts as a "legal high". Am J Med. 2011;124(11):e7-8.
14. Mugele J, Nanagas KA, Tormoehlen LM. Serotonin syndrome associated with MDPV use: a case report. Ann Emerg Med. 2012;60(1):100-2.
15. Caffery T, Musso M, Manausa R, Everett J, Perret J. Riding high on cloud 9. J La State Med Soc. 2012;164(4):186-9.
16. Wells DL, Ott CA. The "new" marijuana. Ann Pharmacother. 2011;45(3):414-7.
17. Atwood BK, Huffman J, Straiker A, Mackie K. JWH018, a common constituent of 'Spice' herbal blends, is a potent and efficacious cannabinoid CB receptor agonist. Br J Pharmacol. 2010;160(3):585-93.
18. Auwarter V, Dresen S, Weinmann W, Muller M, Putz M, Ferreiros N. 'Spice' and other herbal blends: harmless incense or cannabinoid designer drugs? J Mass Spectrom. 2009;44(5):832-7.
19. Jiang W, Zhang Y, Xiao L, et al. Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects. J Clin Invest. 2005;115(11):3104-16. (Pubitemid 41567575)
20. Zimmermann US, Winkelmann PR, Pilhatsch M, Nees JA, Spanagel R, Schulz K. Withdrawal phenomena and dependence syndrome after the consumption of "spice gold". Dtsch Arztebl Int. 2009;106(27):464-7.
21. Moussouttas M. Cannabis use and cerebrovascular disease. Neurologist. 2004;10(1):47-53. (Pubitemid 38140838)
22. Forrester MB, Kleinschmidt K, Schwarz E, Young A. Synthetic cannabinoid and marijuana exposures reported to poison centers. Human & Experimental Toxicology. 2012;31(10):1006-11.
23. Heath TS, Burroughs Z, Thompson AJ, Tecklenburg FW. Acute intoxication caused by a synthetic cannabinoid in two adolescents. J Pediatr Pharmacol Ther. 2012;17(2):177-81.
24. EMCDDA | Drug profile: Synthetic cannabinoids and 'Spice'. 2013; http://www.emcdda.europa.eu/publications/drug-profiles/synthetic-cannabinoids. Accessed October 18, 2013.
25. Vardakou I, Pistos C, Spiliopoulou C. Spice drugs as a new trend: mode of action, identification and legislation. Toxicol Lett. 2010;197(3):157-62.
26. Mir A, Obafemi A, Young A, Kane C. Myocardial infarction associated with use of the synthetic cannabinoid K2. Pediatrics. 2011;128(6):e1622-7.
27. Vearrier D, Osterhoudt KC. A teenager with agitation: higher than she should have climbed. Pediatr Emerg Care. 2010;26(6):462-5.
28. Muller H, Sperling W, Kohrmann M, Huttner HB, Kornhuber J, Maler JM. The synthetic cannabinoid Spice as a trigger for an acute exacerbation of cannabis induced recurrent psychotic episodes. Schizophr Res. Netherlands. 2010;118:309-10.
29. Durand D, Delgado LL, de la Parra-Pellot DM, Nichols-Vinueza D. Psychosis and Severe Rhabdomyolysis Associated with Synthetic Cannabinoid Use. Clin Schizophr Relat Psychoses. Mar 21 2013: 1-13.
30. Acute kidney injury associated with synthetic cannabinoid use-multiple states, 2012. MMWR Morb Mortal Wkly Rep. 2013;62(6):93-8.
31. Kazory A, Aiyer R. Synthetic marijuana and acute kidney injury: an unforeseen association. Clinical Kidney Journal. 2013;6(3):330-3.
32. Daccarett M, Freih M, Machado C. Acute cannabis intoxication mimicking brugada-like ST segment abnormalities. Int J Cardiol. Netherlands. 2007;119:235-6.
33. Mittleman MA, Lewis RA, Maclure M, Sherwood JB, Muller JE. Triggering myocardial infarction by marijuana. Circulation. 2001;103(23):2805-9. (Pubitemid 32550068)
34. Kosior DA, Filipiak KJ, Stolarz P, Opolski G. Paroxysmal atrial fibrillation in a young female patient following marijuana intoxication-a case report of possible association. Med Sci Monit. 2000;6(2):386-9. (Pubitemid 30313183)
35. Wilens TE, Biederman J, Spencer TJ. Case study: adverse effects of smoking marijuana while receiving tricyclic antidepressants. J Am Acad Child Adolesc Psychiatry. 1997;36(1):45-8. (Pubitemid 27024227)
36. Mouzak A, Agathos P, Kerezoudi E, Mantas A, Vourdeli-Yiannakoura E. Transient ischemic attack in heavy cannabis smokers - how 'safe' is it? Eur Neurol. 2000;44(1):42-4. (Pubitemid 30456791)
37. Hoyte CO, Jacob J, Monte AA, Al-Jumaan M, Bronstein AC, Heard KJ. A characterization of synthetic cannabinoid exposures reported to the National Poison Data System in 2010. Ann Emerg Med. 2012;60(4):435-8.
38. D'Souza DC, Sewell RA, Ranganathan M. Cannabis and psychosis/ schizophrenia: human studies. Eur Arch Psychiatry Clin Neurosci. 2009;259(7):413-31.
39. Yucel M, Solowij N, Respondek C, et al. Regional brain abnormalities associated with long-term heavy cannabis use. Arch Gen Psychiatry. 2008;65(6):694-701. (Pubitemid 351787240)
40. Sobolevsky T, Prasolov I, Rodchenkov G. Detection of JWH-018 metabolites in smoking mixture post-administration urine. Forensic Sci Int. 2010;200(1-3):141-7.
41. Jerry J, Collins G, Streem D. Synthetic legal intoxicating drugs: the emerging 'incense' and 'bath salt' phenomenon. Cleve Clin J Med. 2012;79(4):258-64.